Ledger.Open graph →
SEC Form D · filed February 11, 2015

Lysosomal Therapeutics, Inc

Offering
$20.0M
Sold
$10.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (19)

Robert Carpenter · Cambridge, MADirectorBruce L. Booth · Cambridge, MADirectorBernard Davitian · Cambridge, MADirectorAnabatic GP, LLC · Oak Brook, ILExecDavid Bree · GEORGETOWN, GRAND CAYMAN, Cayman IslandsExec · DirectorBruce L. Booth · Cambridge, MADirectorThomas E. Lynch · Boca Raton, FLDirector22Nw, LP · Seattle, WADirectorSteven E. Hall · Cambridge, MADirectorDaniel Geffken · Cambridge, MAExecWarren J. Olsen · Denver, CODirectorClay E. Thorp · Cambridge, MADirectorAnabatic Investment Partners, LLC · Oak Brook, ILDirectorLukasz Gottwald · El Segundo, CADirectorKevin E. Harrington · Boca Raton, FLDirectorRussell J. Matthews · Denver, CODirector22Nw Fund GP, LLC · Seattle, WAExec · DirectorCornelis Been · Cambridge, MAExec · DirectorCarole Neuchterlein · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗